Sugar-sweetened beverage intake tied to concentrations of circulating ceramides
Higher concentrations of distinct ceramide species, known to be linked to adverse metabolic health, are associated with cumulative sugar-sweetened beverage (SSB) consumption that contributes to the development of cardiometabolic diseases, suggests a study.
Participants from the Framingham Heart Study’s Offspring Cohort who had three ceramides measured (n=1,561; mean age, 66 years; 59 percent women) were included in this study. SSB consumption was measured four times over ∼14 years.
The authors categorized the participants according to cumulative SSB intake: nonconsumers (0 to <1 SSB serving/mo) and occasional (1 SSB serving/mo to <1 serving/wk), frequent (1 SSB serving/wk to <1 serving/d), and daily (≥ SSB serving/d) consumers.
Multivariable linear regression models were generated to assess the association of cumulative SSB consumption (independent variable) with blood concentrations of ceramides (C16:0, C22:0 and C24:0) and ceramide ratios (C22:0/C16:0 and C24:0/C16:0).
Adjusted models showed a positive association of more frequent cumulative SSB intake with concentrations of the C16:0 and C22:0 ceramides (ptrend<0.05). Daily consumers had higher mean concentrations of the C16:0 (0.01 μg/mL, 95 percent confidence interval [CI], 0.002–0.017 µg/mL) and C22:0 ceramides (0.06 µg/mL, 95 percent CI, 0.018–0.092 µg/mL) than nonconsumers.
Results persisted when modeling continuous cumulative SSB consumption per 1 serving/d.
Effect modification by diabetes status was noted in the association between cumulative SSB consumption and concentrations of the C24:0 ceramide (pinteraction=0.014). Stratified analysis further revealed a positive correlation between more frequent cumulative SSB intake and concentrations of the C24:0 ceramide only in individuals with prediabetes or diabetes (ptrend=0.001).
“Ceramides have been implicated in the pathogenesis of type 2 diabetes and cardiovascular disease,” the authors said.